Ultragenyx’s ultra-expensive ultra-rare disease drug earns second nod; Another round of promising NASH data
→ Ultragenyx’s Crysvita has scored its second FDA approval, earning the nod to treat bone softening in patients with the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
